Business Context and Reporting Period
This Form 8-K reports the results of the 2022 Annual Meeting of Stockholders held by Atea Pharmaceuticals, Inc. on June 17, 2022. The meeting involved the election of directors, an advisory vote on executive compensation frequency, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 71,947,575 shares were present, representing approximately 86.41% of outstanding common stock. The following proposals were approved:
- Election of Directors: Bruno Lucidi, Polly A. Murphy, D.V.M., Ph.D., and Bruce Polsky, M.D. were elected as Class II Directors to serve until the 2025 Annual Meeting.
- Executive Compensation Frequency: Stockholders approved holding an advisory vote on executive compensation annually (ONE Year).
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, outlook, risks, contingencies, or unusual items. The Company confirmed it will hold annual advisory votes on executive compensation based on the stockholder approval.
Investor Verification Checklist
- Verify the specific terms of the newly elected directors' service contracts.
- Review the Definitive Proxy Statement filed on April 29, 2022, for detailed background on the proposals.
- Confirm the Company's financial status in the most recent 10-K or 10-Q filings, as this 8-K contains no financial data.